USANA Health Sciences (NYSE:USNA) Updates FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 2.450-2.450 for the period, compared to the consensus earnings per share estimate of 2.500. The company issued revenue guidance of $850.0 million-$850.0 million, compared to the consensus revenue estimate of $861.9 million.

USANA Health Sciences Trading Down 1.6 %

USNA stock traded down $0.57 during midday trading on Tuesday, hitting $34.48. The company’s stock had a trading volume of 117,667 shares, compared to its average volume of 79,922. USANA Health Sciences has a 12 month low of $34.15 and a 12 month high of $56.02. The firm’s 50-day moving average is $38.10 and its 200-day moving average is $42.67. The company has a market cap of $656.88 million, a PE ratio of 10.69, a P/E/G ratio of 1.20 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). The business had revenue of $212.87 million during the quarter, compared to analysts’ expectations of $218.64 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same period last year, the firm posted $0.89 EPS. Analysts expect that USANA Health Sciences will post 2.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on USNA shares. DA Davidson decreased their target price on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

Insider Buying and Selling

In related news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director John Turman Fleming sold 1,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the sale, the director now owns 2,503 shares in the company, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,940 shares of company stock valued at $311,670. 0.33% of the stock is owned by company insiders.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.